Pfizer Inc. (NYSE:PFE) Shares Sold by D L Carlson Investment Group Inc.

D L Carlson Investment Group Inc. cut its stake in Pfizer Inc. (NYSE:PFE) by 3.4% during the 4th quarter, HoldingsChannel reports. The fund owned 78,575 shares of the biopharmaceutical company’s stock after selling 2,776 shares during the period. D L Carlson Investment Group Inc.’s holdings in Pfizer were worth $2,085,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $26,000. Rialto Wealth Management LLC bought a new position in Pfizer in the fourth quarter worth about $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC bought a new position in shares of Pfizer during the fourth quarter valued at approximately $31,000. Finally, Curio Wealth LLC acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of PFE stock opened at $25.20 on Monday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $142.93 billion, a price-to-earnings ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61. The stock’s fifty day simple moving average is $26.06 and its 200-day simple moving average is $26.90. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the business posted $0.10 EPS. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.06% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently commented on PFE shares. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Bank of America restated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, UBS Group lowered their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.